The biotechnology sector is undergoing significant transformation, marked by rapid technological advances and major economic challenges. The integration of artificial intelligence (AI) in research and development (R&D) processes has become a crucial strategic lever to overcome the obstacles posed by the "patent cliff," which threatens to reduce industry revenues by $400 billion. Recent initiatives, such as BioNTech's acquisition of InstaDeep for £562 million and NVIDIA's commitment to generative AI, illustrate the transformative potential of these technologies.